Understand the source comparison
Do Peptides Help With Libido: Peptide Types Comparison
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist in hypothalamus MC4R (paraventricular nucleus) 45–90 minutes subcutaneous FDA-approved (2019) for HSDD in premenopausal women; Phase 3 RCTs FDA-approved as Vyleesi Strongest evidence for central desire pat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (Bremelanotide)
- Melanocortin-4 receptor agonist in hypothalamus
- MC4R (paraventricular nucleus)
- 45–90 minutes subcutaneous
- FDA-approved (2019) for HSDD in premenopausal women; Phase 3 RCTs
- FDA-approved as Vyleesi
- Strongest evidence for central desire pathways; response rate ~25%; narrow therapeutic window
- Kisspeptin-10
- GnRH neuron activation → LH/FSH release → gonadal steroidogenesis
- GPR54 (arcuate nucleus)
- 15–30 minutes IV; 60–120 minutes subcutaneous
- Multiple Phase 2 trials; observational studies in hypogonadism
- Research-only (not FDA-approved)
- Addresses root cause in secondary hypogonadism; requires endocrine workup; limited commercial access
- MK-677 (Ibutamoren)
- Growth hormone secretagogue → IGF-1 elevation → androgen sensitivity & vascular function
- Ghrelin receptor (pituitary & hypothalamus)
- 4–8 weeks for sustained effect
- Phase 2 trials for sarcopenia/frailty; observational libido data
- Research compound (not FDA-approved)
- Indirect mechanism; better suited for metabolic/ageing context; slower onset; requires baseline GH/IGF-1 assessment
- Oxytocin
- Hypothalamic neuropeptide modulating pair bonding, trust, arousal response
- Oxytocin receptor (widespread CNS)
- 20–40 minutes intranasal
- Limited RCT evidence for libido; mostly observational or partner interaction studies
- Prescription (Pitocin for labour induction); intranasal formulations off-label
- Weak evidence for direct libido effect; context-dependent; better studied for social bonding than desire
- Melanotan II
- Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R)
- Multiple melanocortin receptors
- 30–60 minutes subcutaneous
- Limited formal trials; widespread anecdotal use; associated with skin darkening (MC1R)
- Not FDA-approved; banned in several countries
- Broader receptor activation than PT-141; higher side effect rate (nausea, flushing, melanogenesis); not recommended outside supervised research